Congestive heart failure in subjects with thyrotoxicosis in a black community

R C Anakwue
B J C Onwubere
B C Anisiuba
V O Ikeh
A Mbah
S O Ike

Department of Medicine, College of Medicine, University of Nigeria Enugu Campus

Introduction: Thyroid hormone has profound effects on a number of metabolic processes in virtually all tissues but the cardiovascular manifestations are prominent usually creating a hyperdynamic circulatory state. Thyrotoxicosis is not a common cause of congestive heart failure among black communities.

Objectives: To determine the hospital prevalence, clinical characteristics and echocardiographic findings in patients with thyrotoxicosis who present with congestive heart failure (CCF) in the eastern part of Nigeria.

Subjects and methods: A total of 50 subjects aged 15 years and above who were diagnosed as thyrotoxic following clinical and thyroid function tests were consecutively recruited. Fifty age- and sex-matched controls with no clinical or biochemical evidence of thyrotoxicosis and no comorbidities were used as controls. Two-dimensional echocardiography was carried out on all the subjects. CCF was determined clinically and echocardiographically.

Results: Eight patients (5 females and 3 males) out of a total of 50 thyrotoxic patients presented with congestive heart failure.

Conclusion: The study revealed that congestive heart failure can occur in thyrotoxicosis in spite of the associated hyperdynamic condition. The underlying mechanism may include direct damage by autoimmune myocarditis, congestive circulation secondary to excess sodium, and fluid retention.

Keywords: thyrotoxicosis, congestive heart failure, echocardiography, black community

Introduction
Thyroid hormone has profound effects on a number of metabolic processes in virtually all tissues with the cardiovascular manifestations most prominent. Thyrotoxicosis creates a hyperdynamic circulatory state because of a marked fall in peripheral vascular resistance and associated increase in venous return, increased total blood volume, increased cardiac contractility and heart rate. In spite of the increased cardiac contractile state, congestive heart failure with reduced fractional shortening and ejection fraction still occurs in thyrotoxicosis.

Congestive heart failure in thyrotoxicosis may present with normal or reduced left ventricular systolic function and dilated heart. This may result from a combination of hypervolemic burden, tachyarrhythmias, congestive circulation secondary to excess sodium and fluid retention related to hyperthyroidism and secondary autoimmune myocarditis related to Graves’ disease.

Thyrotoxicosis is a rare cause of heart failure and there are very few echocardiographic reports on thyrotoxicosis presenting as congestive heart failure in Nigeria. Kolawole et al studied 50 cases of thyrotoxicosis in Ile-Ife, western Nigeria and
reported that 7 patients (14%) had congestive heart failure. Danbauchi et al1 in Zaria, northern Nigeria reported 11 cases out of 122 thyrotoxicosis patients who had clinical symptoms and signs of heart failure. The authors are not aware of any echocardiographic study on individuals with thyrotoxicosis that has been done in the eastern part of Nigeria, comprising 9 states out of the 36 states of Nigeria. This geographical location embraces about 40 million of the 150 million population of Nigeria.

The purpose of this study was to determine the hospital prevalence, clinical characteristics and echocardiographic findings in patients with thyrotoxicosis who present with congestive heart failure in the eastern part of Nigeria.

Methods
We studied 50 patients who were aged 15 years or older, of both sexes and diagnosed of thyrotoxicosis in the medical outpatients unit of the University of Nigeria Teaching Hospital (UNTH) Enugu, following clinical and thyroid function tests. Thyrotoxic patients were recruited consecutively as they presented in the medical outpatients unit over a one year period. Informed consent was obtained from all the subjects. The Ethical committee of UNTH approved the study.

Patients who were found to be in heart failure following clinical assessment which demonstrated congestive symptoms: breathlessness, paroxysmal nocturnal dyspnea, orthopnea, coughing and leg swelling were identified and recruited into the study. Thyroid function tests were done with kits from Syntron Bioresearch Inc USA.4 The Syntron kits have the following intra-assay coefficient of variation: serum-free tri-iodothyronine (T3) – (6.8%), thyroid-stimulating hormone of (TSH) – (4.3%), total free tri-iodothyronine (T3) – (4.4%), total tetraiodothyronine (T4) – (7.2%).4 Comparison between Syntron kit and Abbot Kit showed a correlation coefficient of 0.09869.4 All the patients had electrocardiography and transthoracic echocardiography done with Sonos 2000 Hewlett Packard machine. Two-dimensional echocardiographic examinations were performed in all subjects with 3.5 MHz transducer according to the recommendations of the American Society of Echocardiography.5

The following were excluded from the study: patients who had pre-existing hypertension, diabetes mellitus, anemia, coronary artery disease, exposure to illicit drugs, herbal or any cardiotoxic agents. All pregnant women were also excluded from the study.

Fifty age- and sex-matched controls with no clinical or biochemical evidence of thyrotoxicosis and no comorbidities were included.

Definitions
The diagnosis of thyrotoxicosis was established in the presence of a serum free T3 > 4.2 pg/L and a concomitant suppressed TSH of <0.5 μU/mL.

Left ventricular systolic dysfunction was defined by any of the following: (i) left ventricular ejection fraction (LVEF) <50%, (ii) fractional shortening (FS) <18%, (iii) cardiac index <2.8 L/min/m², (iv) cardiac output <4 L/min, (v) mean velocity of circumferential fiber shortening <1.02 circ/sec, and (vi) peak aortic systolic velocity <72 cm/sec.

Dilated thyrotoxic heart muscle disease was defined as (i) end diastolic diameter >6.0 cm, (ii) end systolic diameter >2.5 cm, (iii) LVEF < 50%, and (iv) FS < 18%.1,5

Statistical analysis
Continuous variables were expressed as mean ± 1 standard error of mean (SEM). Statistical comparisons were performed using Student’s t-test. Calculations were performed using SPSS software (SPSS Inc., Chicago, IL) P < 0.05 was considered significant.

Results
Demographic characteristics
All the patients were black and came from the eastern part of Nigeria. Eight patients – (16%) (consisting of 5 females and 3 males) out of a total number of 50 thyrotoxic patients presented with congestive heart failure. The patients were predominantly Igbos, with only one from Efik tribe in Akwa Ibom State. Their mean age compared with control was not significantly different. Their mean weight was 56 kg (± 4.1): range 52–72 kg. This is significantly lower than the weight 65 kg (±5.7): range 64–78 kg of the controls (P < 0.05) (Table 1).

Clinical characteristics and thyroid function test
The 8 patients who had congestive heart failure presented with symptoms of congestion, dyspnea, coughing and leg swelling, as well symptoms suggestive of thyrotoxicosis. These included palpitation, heat intolerance, tremulousness, increased sweating. They all had Graves’ disease. The mean heart rate was significantly higher in the thyrotoxicosis patients than in the control (102 bpm vs 78 bpm, P < 0.01) whereas there were no significant differences in the mean systolic blood pressure and the mean diastolic blood pressure between the test group and control.
Echocardiography showed that two out of the five patients with LVEF of <50% were in atrial fibrillation.

**Discussion**

This study has shown that congestive heart failure occurs in thyrotoxicosis patients in eastern Nigeria. In spite of the hyperdynamic state found in thyrotoxicosis, low output heart failure with dilated hearts can occur. Is this a true thyrotoxic heart muscle disease or secondary to hemodynamic conditions found in thyrotoxicosis?

No definitive answer has been given to this question. However studies have demonstrated the presence of fibroblast infiltration and degenerative changes as well as TSH-receptor (TSH-R) in human heart in Graves’ disease. TSH-R mRNA was identified in the human heart using the reverse transcriptase polymerase chain reaction and DNA sequencing. Myocardial damage evidenced by III-labeled monoclonal antimyosin antibodies have also occurred in hyperthyroidism with heart failure and both myocardial damage, and left ventricular dysfunction disappeared after antithyroid therapy.

There are hemodynamic conditions in thyrotoxicosis that may increase cardiac load and stress and predispose to failure. The increased cardiac preload which occurs in thyrotoxicosis may be due to peripheral vasodilatation, activation of the renin–angiotensin–aldosterone system and upregulation of the erythropoietin secretion and red blood cell mass, which in turn will increase total blood volume.

The hospital-based studies by Kolawole et al2 and Danbauchi et al3 showed that 14% and 8% of their patients had heart failure, respectively. These figures are lower than the 16% in our index study. This may possibly be due to the fact that our cohort of patients were pulled from nearby hospitals and late presentation could be largely contributory. It is instructive to know that more of the patients in this study had Graves’ disease (100%), compared to only 52% of Kolawole et al2 patients. Atrial fibrillation, which contributes to heart failure in thyrotoxicosis, was found in 4% in Ife2 and 2% in the Zaria3 studies respectively. These figures are comparable with 4% found in this study.

All the 61 thyrotoxicosis patients studied by Niakara et al9 in Burkina Faso had thyrotoxic heart disease, so it is not surprising that 80.3% of them had heart failure and 24.3% had atrial fibrillation. However, only 54.3% of them had Graves’ disease.

In the study by Siu et al1 in China, 5.8% of their patients had heart failure. In their study there was no significant difference in the incidence of Graves’ disease between patients with and without left ventricular systolic dysfunction.

### Table 1 Clinical, anthropometric data and thyroid function of patients and controls

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Thyrotoxicosis Patients: Mean (±SD)</th>
<th>Control: Mean (±SD)</th>
<th>t-test value</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>44 (3.1)</td>
<td>43.5 (5.2)</td>
<td>0.85</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>56.0 (5.5)</td>
<td>65 (7.6)</td>
<td>-6.4</td>
<td>&lt;0.05*</td>
</tr>
<tr>
<td>Height (meters)</td>
<td>159.5 (6.8)</td>
<td>160.8 (15.9)</td>
<td>1.35</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Body surface area (m²)</td>
<td>1.2 (2.4)</td>
<td>1.6 (0.17)</td>
<td>1.85</td>
<td>&lt;0.05*</td>
</tr>
<tr>
<td>Body mass Index (kg/m²)</td>
<td>22.04 (6.4)</td>
<td>25.09 (5.4)</td>
<td>-1.87</td>
<td>&lt;0.05*</td>
</tr>
<tr>
<td>Pulse (beats/min)</td>
<td>102 (11.9)</td>
<td>78 (5.2)</td>
<td>8.57</td>
<td>&lt;0.01*</td>
</tr>
<tr>
<td>Systolic Blood Pressure (mmHg)</td>
<td>124.2 (12.5)</td>
<td>122.9 (2.8)</td>
<td>0.12</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>Diastolic Blood Pressure (mmHg)</td>
<td>75 (11.4)</td>
<td>79.1 (6.5)</td>
<td>1.5</td>
<td>&gt;0.05</td>
</tr>
<tr>
<td>TSH (µu/mL)</td>
<td>0.28 (0.1)</td>
<td>2.3 (1.5)</td>
<td>20.6</td>
<td>&lt;0.01*</td>
</tr>
<tr>
<td>Total T3 (ng/mL)</td>
<td>4.7 (3.9)</td>
<td>1.5 (1.1)</td>
<td>2.5</td>
<td>&lt;0.01*</td>
</tr>
<tr>
<td>Total T4 (µg/mL)</td>
<td>173 (4.2)</td>
<td>56 (2.1)</td>
<td>20.6</td>
<td>&lt;0.01*</td>
</tr>
<tr>
<td>Free T3 (pg/mL)</td>
<td>5.9 (0.9)</td>
<td>2.3 (0.3)</td>
<td>11.9</td>
<td>&lt;0.01*</td>
</tr>
</tbody>
</table>

**Note:** Represents significant value.

**Abbreviations:** T3, tri-iodothyronine; T4, tetraiodothyronine; TsH, thyroid stimulating hormone.
Table 2 Comparison of proportions of left ventricular systolic dysfunction parameters of thyrotoxicosis patients and control

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Proportions found in Thyrotoxicosis Patients $P_T$</th>
<th>Proportions found in Control $P_C$</th>
<th>t-test value</th>
<th>P-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>LVEFR &lt;50%</td>
<td>0.10</td>
<td>0.00</td>
<td>2.05</td>
<td>&lt;0.05*</td>
</tr>
<tr>
<td>FS &lt;18%</td>
<td>0.12</td>
<td>0.00</td>
<td>2.35</td>
<td>&lt;0.05*</td>
</tr>
<tr>
<td>Cardiac index &lt;2.8 L/min/m$^2$</td>
<td>0.10</td>
<td>0.02</td>
<td>2.52</td>
<td>&lt;0.05*</td>
</tr>
<tr>
<td>Cardiac output &lt;4 L</td>
<td>0.10</td>
<td>0.02</td>
<td>2.1</td>
<td>&lt;0.05*</td>
</tr>
<tr>
<td>Peak aortic systolic velocity &lt;72 cm/s</td>
<td>0.12</td>
<td>0.00</td>
<td>2.30</td>
<td>&lt;0.05*</td>
</tr>
<tr>
<td>VCF(circumferences/second) &lt;1.02</td>
<td>0.10</td>
<td>0.00</td>
<td>2.35</td>
<td>&lt;0.05*</td>
</tr>
</tbody>
</table>

Abbreviations: FS, fractional shortening; VCF, velocity of circumferential fiber shortening; LVEFR, Left ventricular ejection fraction.

Figure 1 Bar chart comparing proportions of thyrotoxicosis patients with and without congestive heart failure using left ventricular ejection fraction as a systolic parameter.

$^*<50%$ = systolic dysfunction, 50%–75% = normal systolic function, >75% = enhanced systolic function.

Vascular Health and Risk Management downloaded from https://www.dovepress.com/ by 54.70.40.11 on 01-Oct-2018
For personal use only.
Powered by TCPDF (www.tcpdf.org)
Dilated hearts, as shown in Figure 2, have been noted in other studies to be associated with reduced LVEF.\(^3,9\) Interestingly, restoring normal levels of thyroid hormone often reverses the dilation and dysfunction, which makes thyrotoxic heart failure a curable disease.

**Conclusion**

Heart failure can occur in thyrotoxicosis in spite of the associated hyperdynamic condition. The underlying mechanism may include direct damage by autoimmune myocarditis, congestive circulation secondary to excess sodium and fluid retention related to hyperthyroidism or diastolic heart failure triggered by sustained tachycardia and or atrial fibrillation.\(^10\) This study has demonstrated that heart failure in thyrotoxicosis may be accompanied with normal or low cardiac output state.

**Disclosure**

The authors declare no conflicts of interest in this work.

**References**


**Figure 2** Two-dimensional echocardiogram showing dilated heart chambers.